Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer
(WorldNews Europe)

Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) METex14 is an important biomarker for physicians to consider when selecting metastatic NSCLC treatment options1 In the US, METex14 metastatic NSCLC is diagnosed in ~4,000-5,000 patients annually and typically indicates aggressive disease with a poor prognosis2-3 Basel, September 2, 2020 - Data from the pivotal GEOMETRY mono-1 Phase II study published today in The New England Journal of Medicine (NEJM) show treatment with Tabrecta™ (capmatinib, formerly INC280) resulted in...